Acebilustat

Generic Name: Acebilustat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₂₇N_₃O_₄

CAS Number: 943764-99-6

Unique Ingredient Identifier: J64RI4D29U

Background: Acebilustat is under investigation in clinical trial NCT01748838 (Phase 1 Study Assessing the Safety and Tolerability of CTX-4430).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Trial of Acebilustat for the Treatment of Upper Arm Lymphedema

Phase 2

Recruiting

Conditions: Lymphedema of Upper Arm

Interventions: Drug: Acebilustat
Drug: Placebo

First Posted Date: 2022-01-24

Last Posted Date: 2024-04-17

Lead Sponsor: Stanford University

Target Recruit Count: 70

Registration Number: NCT05203835

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Acebilustat
Drug: Placebo

First Posted Date: 2020-12-10

Last Posted Date: 2023-06-13

Lead Sponsor: Stanford University

Target Recruit Count: 120

Registration Number: NCT04662060

Locations: 🇺🇸
Stanford University, Stanford, California, United States

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Acebilustat
Drug: Camostat

First Posted Date: 2020-12-10

Last Posted Date: 2023-06-28

Lead Sponsor: Stanford University

Target Recruit Count: 122

Registration Number: NCT04662086

Locations: 🇺🇸
ValleyCare Medical Center, Pleasanton, California, United States
🇺🇸
Stanford University, Stanford, California, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy